Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
INCB177054 · 1 trial · 3 indications
Dose-limiting toxicity will be defined as the occurrence of any of the toxicities as per protocol.
Defined as adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug/treatment.
Number of participants with TEAEs leading to dose modification including interruptions, dose reductions, and discontinuation of study drug.
| Arm | Type | Description |
|---|---|---|
| Part 1a: Dose Escalation monotherapy | EXPERIMENTAL | INCB177054 at the protocol-defined dose strength based on cohort assignment. |
| Part 1b: Pharmacodynamic cohort | EXPERIMENTAL | INCB177054 at the protocol-defined dose strength based on cohort assignment. |
| Part 1c: Dose Expansion monotherapy | EXPERIMENTAL | INCB177054 at the protocol-defined dose strength based on cohort assignment. |
| Part 2a: Dose Escalation combination | EXPERIMENTAL | INCB177054 in combination with retifanlimab at the protocol-defined dose strength based on cohort assignment. |
| Part 2b: Dose Expansion combination | EXPERIMENTAL | INCB177054 in combination with retifanlimab at the protocol-defined dose strength based on cohort assignment. |
| Name | Type | Description |
|---|---|---|
| INCB177054 | DRUG | INCB177054 will be administered at protocol defined dose. |
| Retifanlimab | DRUG | Retifanlimab will be administered at protocol defined dose. |
Inclusion Criteria: * Anticipated life expectancy greater than 12 weeks. * ECOG performance status score of 0 or 1. * Measurable disease per RECIST v1.1 on CT or MRI. * Part 1a and 2a (dose escalation) and Part 1c (dose expansion): participants who have a confirmed tissue diagnosis of a solid malig...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
INCB177054 is an investigational small molecule being studied for the treatment of select advanced or metastatic solid tumors. It is in Phase 1 clinical development for oncology indications, specifically targeting patients with advanced or metastatic solid tumors.
INCB177054 is being developed by Incyte Corporation, a biopharmaceutical company traded on the NASDAQ under the ticker symbol INCY. The company is conducting clinical research on this investigational oncology drug candidate.
INCB177054 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials to evaluate its safety and efficacy in patients with advanced or metastatic solid tumors.
INCB177054 is being evaluated in a Phase 1 clinical trial with the identifier NCT06873789. This study, titled 'A Study to Evaluate INCB177054 in Participants With Select Advanced or Metastatic Solid Tumors,' was conducted in the United States and enrolled 9 participants aged 18 years and older.
INCB177054 is the primary name for this investigational drug candidate developed by Incyte Corporation. No alternative names have been reported for this compound in the available clinical trial information.